InMed Pharmaceuticals(INM)

VANCOUVER, British Columbia, CanadaPharmaceutical

Focus: InMed Pharmaceuticals is a public Canadian biotech focused on cannabinoid therapeutics and database development, currently in early-stage clinical programs targeting neurology and dermatology indications. The company is transitioning from commercial operations (BayMedica) toward drug development with minimal revenue generation.

Neurology

Profile data last refreshed 8h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About InMed Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow InMed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$5M

FY2025

Pipeline & Clinical Trials

INM-755

Epidermolysis Bullosa Simplex

PHASE_2

Clinical Trials (1)

NCT04908215INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Phase 2

Help build intelligence for InMed Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Emerging cannabinoid science platform with 70% R&D intensity offers scientists exposure to a frontier therapeutic area with regulatory novelty
Public company status provides equity upside potential and access to capital markets visibility
Phase 2 program (INM-755 in Epidermolysis Bullosa Simplex) represents early clinical validation opportunity for cannabinoid mechanism

Watch Out For

Severe financial distress: $7.7M net loss on $5M revenue (FY 2025), with cash declining from $9M to $7M; runway sustainability uncertain
Zero active hiring and no open positions signal organizational contraction or severe resource constraints
Single Phase 2 program and no Phase 3 catalysts limit near-term clinical and commercial upside; commercial wind-down of BayMedica (May 2026) suggests business model reset

Generated by Claude from InMed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$5M11%

R&D Spend

$3M(70%)14%

Net Income

-$8M

Cash

$7M

Source: SEC 10-K Filing

Risk Signals

May 2026 wind-down of BayMedica commercial operations represents significant business contraction, though specific headcount reductions not disclosed in available reports.

Recent commercial operation shutdown and widening losses in Q1 FY 2026 ($660K revenue, -$0.73 EPS) signal active restructuring; job security and advancement prospects are elevated risk.